Related references
Note: Only part of the references are listed.Seven-Year Efficacy of RTS, S/AS01 Malaria Vaccine among Young African Children
Ally Olotu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The March Toward Malaria Vaccines
Stephen L. Hoffman et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2015)
Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains
Raul Herrera et al.
INFECTION AND IMMUNITY (2015)
Development of a transmission-blocking malaria vaccine: Progress, challenges, and the path forward
Julia K. Nunes et al.
VACCINE (2014)
Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites
Selidji Todagbe Agnandji et al.
PLOS MEDICINE (2014)
Malaria vaccines: past, present and future
Lorenz von Seidlein et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2013)
Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays
Kazutoyo Miura et al.
PLOS ONE (2013)
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Robert A. Seder et al.
SCIENCE (2013)
Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle
Richard L. Shimp et al.
VACCINE (2013)
Vaccination and herd immunity: what more do we know?
Harunor Rashid et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2012)
Measuring the blockade of malaria transmission - An analysis of the Standard Membrane Feeding Assay
Thomas S. Churcher et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2012)
Phase 1 Study in Malaria Naive Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria
Ruth D. Ellis et al.
PLOS ONE (2012)
The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant Vaccines
Vu Dinh Thiem et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species
Lediya Cheru et al.
VACCINE (2010)
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children
Justen H. Passwell et al.
VACCINE (2010)
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu et al.
PLOS ONE (2008)
Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines
Kazutoyo Miura et al.
VACCINE (2008)
Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders
Feng Qian et al.
VACCINE (2008)
Mosquito stage, transmission blocking vaccines for malaria
Allan Saul
CURRENT OPINION IN INFECTIOUS DISEASES (2007)
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A:: A strategy for enhancing immunogenicity of malaria vaccine candidates
Feng Qian et al.
VACCINE (2007)
Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P-pastoris
CW Tsai et al.
JOURNAL OF BIOTECHNOLOGY (2006)
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children
JH Passwell et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2003)
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children
FYC Lin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
